Hong Kong listed WuXi Biologics to operate Bayer’s final drug product manufacturing plants in Leverkusen, Germany

Plants in Leverkusen will be operated by WuXi Biologics and will serve as a back-up site for final product manufacturing of Kovaltry™. Photo: T Branding. 

(PRESS RELEASE) LEVERKUSEN, 16-Jan-2020 — /EuropaWire/ —  Life science, health care and nutrition global enterprise Bayer announced that the leading global open-access biologics technology firm WuXi Biologics (WuXi Bio), listed in Hong Kong (stock code: 2269.HK), through its subsidiary in Germany WuXi Biologics Germany GmbH will acquire its final drug product manufacturing plants in Leverkusen, Germany. According to the deal terms WuXi Biologics will also purchase the associated equipment, in combination with a long-term lease contract for the building. The transaction is subject to the satisfaction of customary closing conditions and is expected to close within the new few months. Financial details of the deal have not been disclosed.

According to further manufacturing agreements yet to be negotiated, the newly acquired plants in Leverkusen, will be operated by WuXi Biologics and will serve as a back-up site for final product manufacturing of Kovaltry™ (antihemophilic factor /recombinant/). Bayer’s drug substance and drug product facility in Berkeley, California, USA, on the other side, will remain the major site for the manufacturing and filling of it.

Media contact:

Hans-Bernd Schmitz
Phone: +49 214 30-81341
Email: hans-bernd.schmitz@bayer.com

SOURCE: Bayer

Logos:

Bayer logo

WuXi Biologics logo